PD-1/PD-L1 Checkpoint Inhibitors - Global Top Players Market Share and Ranking 2025- YH Research

Home > Reports >Pharma & Healthcare > PD-1/PD-L1 Checkpoint Inhibitors - Global Top Players Market Share and Ranking 2025

PD-1/PD-L1 Checkpoint Inhibitors - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-12-12
Report Id: 2862799
Industry: Pharma & Healthcare
Report Page: 108
Chart: 105

PDF Download

Publication Date: 2025-12-12
Report Id: 2862799
Industry: Pharma & Healthcare
Report Page: 108
Chart: 105

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 PD-1/PD-L1 Checkpoint Inhibitors Definition
1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size and Forecast
1.2.1 By Consumption Value, Global PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
1.2.2 By Sales Quantity, Global PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
1.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Selling Price (ASP), 2020-2031
1.3 China PD-1/PD-L1 Checkpoint Inhibitors Market Size and Forecast
1.3.1 By Consumption Value, China PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
1.3.2 By Sales Quantity, China PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
1.3.3 China PD-1/PD-L1 Checkpoint Inhibitors Average Selling Price (ASP), 2020-2031
1.4 Share of China PD-1/PD-L1 Checkpoint Inhibitors Market with Respect to the Global Market
1.4.1 By Consumption Value, China PD-1/PD-L1 Checkpoint Inhibitors Market Share in Global, 2020-2031
1.4.2 By Sales Quantity, China PD-1/PD-L1 Checkpoint Inhibitors Market Share in Global, 2020-2031
1.4.3 PD-1/PD-L1 Checkpoint Inhibitors Market Size: China VS Global, 2020-2031
1.5 PD-1/PD-L1 Checkpoint Inhibitors Market Dynamics
1.5.1 PD-1/PD-L1 Checkpoint Inhibitors Market Drivers
1.5.2 PD-1/PD-L1 Checkpoint Inhibitors Market Restraints
1.5.3 PD-1/PD-L1 Checkpoint Inhibitors Industry Trends
1.5.4 PD-1/PD-L1 Checkpoint Inhibitors Industry Policy

2 Global Leading Manufacturers and Market Share
2.1 By Revenue of PD-1/PD-L1 Checkpoint Inhibitors, Global Market Share by Company, 2020-2025
2.2 By Sales Quantity of PD-1/PD-L1 Checkpoint Inhibitors, Global Market Share by Company, 2020-2025
2.3 PD-1/PD-L1 Checkpoint Inhibitors Average Selling Price (ASP) by Company, 2020-2025
2.4 Global PD-1/PD-L1 Checkpoint Inhibitors Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global PD-1/PD-L1 Checkpoint Inhibitors Concentration Ratio
2.6 Global PD-1/PD-L1 Checkpoint Inhibitors Mergers & Acquisitions, Expansion Plans
2.7 Global PD-1/PD-L1 Checkpoint Inhibitors Manufacturers Product Type
2.8 Head Office and PD-1/PD-L1 Checkpoint Inhibitors Production Site of Key Manufacturer
2.9 PD-1/PD-L1 Checkpoint Inhibitors Capacity of Major Manufacturers and Future Plan

3 China Leading Manufacturers and Market Share
3.1 By Revenue of PD-1/PD-L1 Checkpoint Inhibitors, China Market Share by Company, 2020-2025
3.2 By Sales Quantity of PD-1/PD-L1 Checkpoint Inhibitors, China Market Share by Company, 2020-2025
3.3 China PD-1/PD-L1 Checkpoint Inhibitors PD-1/PD-L1 Checkpoint Inhibitors Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Global Producing Regions
4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Capacity, Output and Capacity Utilization, 2020-2031
4.2 Global PD-1/PD-L1 Checkpoint Inhibitors Capacity by Region
4.3 Global PD-1/PD-L1 Checkpoint Inhibitors Production & Forecast by Region, 2020 VS 2024 VS 2031
4.4 Global PD-1/PD-L1 Checkpoint Inhibitors Production by Region, 2020-2031
4.5 Global PD-1/PD-L1 Checkpoint Inhibitors Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Chain
5.2 PD-1/PD-L1 Checkpoint Inhibitors Upstream Analysis
5.2.1 PD-1/PD-L1 Checkpoint Inhibitors Core Raw Materials
5.2.2 Main Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 PD-1/PD-L1 Checkpoint Inhibitors Production Mode
5.6 PD-1/PD-L1 Checkpoint Inhibitors Procurement Model
5.7 PD-1/PD-L1 Checkpoint Inhibitors Industry Sales Model and Sales Channels
5.7.1 PD-1/PD-L1 Checkpoint Inhibitors Sales Model
5.7.2 PD-1/PD-L1 Checkpoint Inhibitors Typical Distributors

6 Sights by Type
6.1 PD-1/PD-L1 Checkpoint Inhibitors Classification by Type
6.1.1 PD-1 Inhibitors
6.1.2 PD-L1 Inhibitors
6.2 by Type, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020-2031
6.4 by Type, Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, 2020-2031
6.5 by Type, Global PD-1/PD-L1 Checkpoint Inhibitors Average Selling Price (ASP), 2020-2031

7 Sights by Product Name
7.1 PD-1/PD-L1 Checkpoint Inhibitors Classification by Product Name
7.1.1 Pembrolizumab
7.1.2 Nivolumab
7.1.3 Cemiplimab
7.1.4 Toripalimab
7.1.5 Sintilimab
7.1.6 Tislelizumab
7.1.7 Camrelizumab
7.1.8 Penpulimab
7.1.9 Retifanlimab
7.2 by Product Name, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Product Name, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020-2031
7.4 by Product Name, Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, 2020-2031
7.5 by Product Name, Global PD-1/PD-L1 Checkpoint Inhibitors Average Selling Price (ASP), 2020-2031

8 Sights by Dosage Strength
8.1 PD-1/PD-L1 Checkpoint Inhibitors Classification by Dosage Strength
8.1.1 100 mg / Vial
8.1.2 200 mg / Vial
8.1.3 240 mg / Vial
8.1.4 300 mg / Vial
8.2 by Dosage Strength, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Dosage Strength, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020-2031
8.4 by Dosage Strength, Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, 2020-2031
8.5 by Dosage Strength, Global PD-1/PD-L1 Checkpoint Inhibitors Average Selling Price (ASP), 2020-2031

9 Sights by Application
9.1 PD-1/PD-L1 Checkpoint Inhibitors Segment by Application
9.1.1 Squamous Cell Skin Cancer
9.1.2 Non-small Cell Lung Cancer
9.1.3 Melanoma
9.1.4 Gastric Cancer
9.1.5 Other
9.2 by Application, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value & CAGR, 2020 VS 2024 VS 2031
9.3 by Application, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020-2031
9.4 by Application, Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, 2020-2031
9.5 by Application, Global PD-1/PD-L1 Checkpoint Inhibitors Price, 2020-2031

10 Sales Sights by Region
10.1 By Region, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020 VS 2024 VS 2031
10.2 By Region, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020-2031
10.3 By Region, Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, 2020-2031
10.4 North America
10.4.1 North America PD-1/PD-L1 Checkpoint Inhibitors Market Size & Forecasts, 2020-2031
10.4.2 By Country, North America PD-1/PD-L1 Checkpoint Inhibitors Market Size Market Share
10.5 Europe
10.5.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size & Forecasts, 2020-2031
10.5.2 By Country, Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size Market Share
10.6 Asia Pacific
10.6.1 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size & Forecasts, 2020-2031
10.6.2 By Country/Region, Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size Market Share
10.7 South America
10.7.1 South America PD-1/PD-L1 Checkpoint Inhibitors Market Size & Forecasts, 2020-2031
10.7.2 By Country, South America PD-1/PD-L1 Checkpoint Inhibitors Market Size Market Share
10.8 Middle East & Africa

11 Sales Sights by Country Level
11.1 By Country, Global PD-1/PD-L1 Checkpoint Inhibitors Market Size & CAGR, 2020 VS 2024 VS 2031
11.2 By Country, Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, 2020-2031
11.3 By Country, Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, 2020-2031
11.4 United States
11.4.1 United States PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.4.2 by Type, United States PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.4.3 by Application, United States PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.5 Europe
11.5.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.5.2 by Type, Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.5.3 by Application, Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.6 China
11.6.1 China PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.6.2 by Type, China PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.6.3 by Application, China PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.7 Japan
11.7.1 Japan PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.7.2 by Type, Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.7.3 by Application, Japan PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.8 South Korea
11.8.1 South Korea PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.8.2 by Type, South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.8.3 by Application, South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.9 Southeast Asia
11.9.1 Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.9.2 by Type, Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.9.3 by Application, Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.10 India
11.10.1 India PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.10.2 by Type, India PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.10.3 by Application, India PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.11 Middle East & Africa
11.11.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2020-2031
11.11.2 by Type, Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031
11.11.3 by Application, Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share, 2024 VS 2031

12 Manufacturers Profile
12.1 Bristol Myers Squibb
12.1.1 Bristol Myers Squibb Company Information, Head Office, Market Area, and Industry Position
12.1.2 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.1.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.1.4 Bristol Myers Squibb Company Profile and Main Business
12.1.5 Bristol Myers Squibb Recent Developments
12.2 Merck
12.2.1 Merck Company Information, Head Office, Market Area, and Industry Position
12.2.2 Merck PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.2.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.2.4 Merck Company Profile and Main Business
12.2.5 Merck Recent Developments
12.3 Regeneron Pharmaceuticals
12.3.1 Regeneron Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
12.3.2 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.3.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.3.4 Regeneron Pharmaceuticals Company Profile and Main Business
12.3.5 Regeneron Pharmaceuticals Recent Developments
12.4 Roche
12.4.1 Roche Company Information, Head Office, Market Area, and Industry Position
12.4.2 Roche PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.4.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.4.4 Roche Company Profile and Main Business
12.4.5 Roche Recent Developments
12.5 Pfizer
12.5.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
12.5.2 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.5.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.5.4 Pfizer Company Profile and Main Business
12.5.5 Pfizer Recent Developments
12.6 AstraZeneca
12.6.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
12.6.2 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.6.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.6.4 AstraZeneca Company Profile and Main Business
12.6.5 AstraZeneca Recent Developments
12.7 Hengrui Pharmaceuticals
12.7.1 Hengrui Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
12.7.2 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.7.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.7.4 Hengrui Pharmaceuticals Company Profile and Main Business
12.7.5 Hengrui Pharmaceuticals Recent Developments
12.8 Junshi Biosciences
12.8.1 Junshi Biosciences Company Information, Head Office, Market Area, and Industry Position
12.8.2 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.8.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.8.4 Junshi Biosciences Company Profile and Main Business
12.8.5 Junshi Biosciences Recent Developments
12.9 Innovent
12.9.1 Innovent Company Information, Head Office, Market Area, and Industry Position
12.9.2 Innovent PD-1/PD-L1 Checkpoint Inhibitors Models, Specifications, and Application
12.9.3 Innovent PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.9.4 Innovent Company Profile and Main Business
12.9.5 Innovent Recent Developments

13 Conclusion

14 Appendix
14.1 Research Methodology
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Market Estimation Model
14.4 Disclaimer

According to YH Research, the global market for PD-1/PD-L1 Checkpoint Inhibitors should grow from US$ 56337 million in 2024 to US$ 112639 million by 2031, with a CAGR of 10.5% for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

PD-1/PD-L1 Checkpoint Inhibitors

According to YH Research, the global market for PD-1/PD-L1 Checkpoint Inhibitors should grow from US$ 56337 million in 2024 to US$ 112639 million by 2031, with a CAGR of 10.5% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

PD-1/PD-L1 checkpoint inhibitors are a class of immuno-oncology therapies designed to block the immune-suppressive signaling pathway that tumors exploit to deactivate T-cell–mediated antitumor immunity. These agents address the unmet need of patients whose tumors are resistant or poorly responsive to conventional chemotherapy and targeted therapies. The concept emerged as researchers uncovered how malignant cells overexpress PD-L1 or engage PD-1 on T cells to evade immune surveillance; the development of monoclonal antibodies capable of binding and blocking these proteins led to a therapeutic breakthrough, with the first approvals in 2014 reshaping cancer treatment worldwide. Their development and manufacturing rely on an upstream supply chain that includes cell line development materials, recombinant protein expression systems, culture media, buffers, filtration consumables, bioreactors, and aseptic filling components. This also covers nucleic acid materials for antibody engineering, analytical reagents, and instrumentation essential for quality control, forming a comprehensive upstream ecosystem that ensures product consistency, safety, and clinical performance. In 2024, global sales of PD-1/PD-L1 checkpoint inhibitors reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.

From a market perspective, the PD-1/PD-L1 inhibitor landscape has transitioned from a narrow set of indications to a broad, heterogeneous adoption across cancer types and treatment lines, accompanied by an increasingly crowded supplier ecosystem. Market dynamics are shaped not only by competing products but also by a growing ancillary industry of diagnostic developers, contract manufacturers and service providers that support clinical translation and commercialization. Regional differences in clinical guidelines, payer policies and healthcare infrastructure further lead to heterogeneous uptake patterns, even as overall clinical familiarity and guideline inclusion continue to strengthen usage.

Looking ahead, two complementary trends will dominate: precision immunotherapy and rational combinations. Precision approaches that integrate tumor genomics, immune microenvironment profiling and predictive biomarkers will refine patient selection and improve benefit–risk ratios, while combination regimens aim to broaden responder populations and delay or overcome resistance. Concurrently, platform innovations — such as engineered antibodies, bispecific constructs, long-acting formats and localized delivery systems — will diversify the therapeutic toolbox and open niche application opportunities.

Key growth drivers include persistent unmet clinical needs, robust R&D funding, and evolving regulatory frameworks that increasingly accommodate breakthrough immunotherapies; clinician experience and patient advocacy also accelerate adoption. Major constraints remain: intrinsic and acquired resistance in certain tumor types, uneven access driven by cost and reimbursement variability, and the high technical and capital barriers of biologics development and manufacturing. The interplay among scientific advances, payer decisions and real-world evidence generation will determine how rapidly and equitably these therapies diffuse into broader oncology practice.

This report studies and analyses global PD-1/PD-L1 Checkpoint Inhibitors status and future trends, helps the client to determine the PD-1/PD-L1 Checkpoint Inhibitors market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for PD-1/PD-L1 Checkpoint Inhibitors, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2024 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global PD-1/PD-L1 Checkpoint Inhibitors market size, history data 2020-2025, and forecast data 2026-2031, (US$ million) & (K Units)
(2) Global PD-1/PD-L1 Checkpoint Inhibitors sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(3) China PD-1/PD-L1 Checkpoint Inhibitors sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(4) Global PD-1/PD-L1 Checkpoint Inhibitors key consuming regions, consumption quantity, consumption value and demand structure
(5) Global PD-1/PD-L1 Checkpoint Inhibitors key producing regions, capacity, production, and year over year growth
(6) PD-1/PD-L1 Checkpoint Inhibitors industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Bristol Myers Squibb
    Merck
    Regeneron Pharmaceuticals
    Roche
    Pfizer
    AstraZeneca
    Hengrui Pharmaceuticals
    Junshi Biosciences
    Innovent

Market segment by Type, covers
    PD-1 Inhibitors
    PD-L1 Inhibitors

Market segment by Product Name, covers
    Pembrolizumab
    Nivolumab
    Cemiplimab
    Toripalimab
    Sintilimab
    Tislelizumab
    Camrelizumab
    Penpulimab
    Retifanlimab
    Zimberelimab
    Atezolizumab
    Durvalumab
    Avelumab
    Envafolimab
    Adebrelimab

Market segment by Dosage Strength, covers
    100 mg / Vial
    200 mg / Vial
    240 mg / Vial
    300 mg / Vial

Market segment by Application, can be divided into
    Squamous Cell Skin Cancer
    Non-small Cell Lung Cancer
    Melanoma
    Gastric Cancer
    Other

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe PD-1/PD-L1 Checkpoint Inhibitors product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global PD-1/PD-L1 Checkpoint Inhibitors market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 3: China PD-1/PD-L1 Checkpoint Inhibitors market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 4: Global key producing regions of PD-1/PD-L1 Checkpoint Inhibitors, percent & CAGR, 2020-2031
Chapter 5: PD-1/PD-L1 Checkpoint Inhibitors industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.